Blog

Under the terms of this business collaboration, PROFI boosted with network of FSBI Pirogov NMSC of the Ministry of Health of the Russian Federation, State Medical University will facilitate unique tumor samples and genomics data based platforms to Oncologics for the discovery and preclinical development of it’s pipeline.Oncologics has created a repository of Indian cancer patients surgically extracted tumor tissues as platform assets supporting it’s breakthrough small molecules discovery program. As the work continues, PROFI will have the chance to exercise options, commercial rights on pipeline being developed to the point of Investigational New Drug (IND) status. Owing to PROFI’s local presence in Russia and it’s relationships with Pharma and Russian Academy of Sciences., the distributor rights on Oncologics’s cell based products for drug discovery and cosmetic testings is a win-win business opportunity for both the parties.
Oncologics has a proven track record in discovery collaborations with SignMod, Dana Farber Cancer Institute, USA, McGill University, Lady Davis Institute for Medical Research, Canada, Vydehi Institute of Medical Research, B’lore. The Company has filed 2 patents on first-in-class macrocyclic small molecules discovered as Wnt transcription inhibitors and are in talks with India and global Pharma exploring to build revenue generation channels from discovery programs. The group’s expertise on adult stem cell technologies complemented by track record in first-in-class nature inspired organic and medicinal chemistry becomes the foundation in building pipeline of lead candidates.
Oncologics’s unique cell based products targeting drug discovery and cosmetic testings global market opportunity is building it’sIndia and international users database by it’s local presence in India, through distributors/channel partners out of India.

Transcell Oncologics is a wholly-owned subsidiary of Transcell Biologics Pvt. Ltd. It is based in Hyderabad while the vision of the Company is to translate adult stem cell technology prowess into cancer clinical reality.